Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NADK | O95544 | 2/20 | 0.72 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.71 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.71 |
| ▸ | FBP1 | P09467 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8628967 | 1.00 | NADK (0.72) | NADKHSPA5HSPA8FBP1RXFP1 | |
| Phosphoric Acid SCHEMBL5007800 | 1.00 | NADK (0.72) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL440926 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL6671819 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL20419274 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL12030991 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL1106674 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL440925 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL13587343 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 | |
| SCHEMBL14435669 | 0.94 | NADK (0.79) | NADKHSPA5HSPA8FBP1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214789-A1 | Therapeutics | POTTER BARRY V L (GB) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214789-A1 | Therapeutics | CD38, ADCY1, ADCY2 | NADK 59/4885HSPA5 2894/4885HSPA8 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.